You are not logged in.

Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: promising potential for targeting radiosensitive retinoblastoma

Samuel, Jaisy, Singh, Narinderbir, Kanwar, Jagat Rakesh, Krishnakumar, Subramanium and Kanwar, Rupinder Kaur 2015, Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: promising potential for targeting radiosensitive retinoblastoma, Experimental eye research, vol. 139, pp. 108-114, doi: 10.1016/j.exer.2015.07.011.

Attached Files
Name Description MIMEType Size Downloads

Title Upregulation of sodium iodide symporter (NIS) protein expression by an innate immunity component: promising potential for targeting radiosensitive retinoblastoma
Author(s) Samuel, Jaisy
Singh, Narinderbir
Kanwar, Jagat RakeshORCID iD for Kanwar, Jagat Rakesh orcid.org/0000-0003-3728-9568
Krishnakumar, Subramanium
Kanwar, Rupinder Kaur
Journal name Experimental eye research
Volume number 139
Start page 108
End page 114
Total pages 7
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015
ISSN 1096-0007
Keyword(s) Bovine lactoferrin
Enhanced expression
Lactoferrin receptors
Retinoblastoma
Sodium iodide symporter
Summary Retinoblastoma (RB), a malignant tumour of the eye arising from developing retina, is the most frequent primary intraocular malignancy of childhood. Its primary management with chemotherapy involves combination regimen of etoposide, vincristine and carboplatin and intra vitreal chemotherapy using melphalan when vitreous seeds develop. Radiotherapy is another effective mode in treating RB. We recently explored the notion if radiotherapy in RB can be mediated via Sodium Iodide Symporter (NIS), an intrinsic membrane glycoprotein which is a key regulator of iodide access to thyroid gland. Its expression has been exploited successfully for diagnostic imaging and molecular radionuclide-based therapy of thyroid cancer. We determined that NIS is expressed endogenously in RB tumour tissues, and in retinoblastoma cell lines Y79 and Weri-Rb-1, and therefore made an attempt to enhance the endogenously low expression of NIS protein in both Y79 and Weri-Rb-1 cells. Here we report about the potential of bovine lactoferrin (bLf) which is a known chemo preventive and emerging safe anti-cancer bio drug, as well as a natural transcriptional activator of genes, to enhance the endogenous expression of NIS in Y79 and Weri-Rb-1 cells. Real time PCR revealed that both cell lines express mRNA of lactoferrin receptors while flow cytometry and confocal microscopy showed the cells efficiently internalize bLf which upregulates NIS expression. These findings highlight an important step that could be taken towards the development of less harmful approaches for the treatment of RB by employing natural supplement bLf (with its clinically proven safe profile), and warrants further studies in future, focussing on enhancing NIS expression in RB cells and NIS functional assays in these cells.
Language eng
DOI 10.1016/j.exer.2015.07.011
Field of Research 110399 Clinical Sciences not elsewhere classified
Socio Economic Objective 920199 Clinical Health (Organs, Diseases and Abnormal Conditions) not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30078107

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 135 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Wed, 14 Oct 2015, 12:43:16 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.